Fibrotic microtissue array to predict anti-fibrosis drug efficacy

Area of Science:

• Biomedical Engineering
• Pulmonary Medicine
• Tissue Engineering

Background:

• Fibrosis is a progressive stiffening of tissues leading to organ damage.
• Current in vitro models lack the dynamic mechanical properties of fibrogenesis.
• Developing effective anti-fibrosis therapies is hindered by inadequate modeling systems.

Purpose of the Study:

• To create a novel in vitro model of lung fibrosis that recapitulates key biomechanical changes.
• To assess the therapeutic efficacy of FDA-approved anti-fibrosis drugs using this new model.

Main Methods:

• Development of membranous human lung microtissues.
• Modeling of progressive stiffening, contraction, compliance decline, and bronchial dilation.
• Phenotypic analysis of anti-fibrosis drug efficacy (Pirfenidone, Nintedanib).

Main Results:

• The microtissue model successfully replicated dynamic biomechanical events of lung fibrogenesis.
• Preventative treatment with Pirfenidone and Nintedanib reduced tissue contractility and prevented stiffening.
• Therapeutic treatment with both drugs restored tissue compliance.

Conclusions:

• The novel fibrotic microtissue system provides a pathologically relevant platform for studying fibrosis.
• This model enables multi-parameter, phenotypic analysis of anti-fibrosis drug efficacy.
• The system demonstrates the potential for advancing the development of anti-fibrosis therapies.